Ares Capital remains fundamentally strong with a diversified portfolio, but lagging performance is a problem. See why ARCC stock is downgraded to buy.

Arcutis Biotherapeutics is a standout in biotech with FDA-approved ZORYVE and strong potential. See why we recommend a buy on ...